Redeye is encouraged by the sales beat in the quarter and notes that the high demand accelerated throughout the quarter. At the same time, the operating loss was higher than we expected. We think the company needs to decide between continuing to invest for growth and raising capital, or focusing on cash flow. We argue that the risk has increased and reduce our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ngenic - Growth vs Cash Management

© Modular Finance, source Nordic Press Releases